Key facts
- Primmune Therapeutics’s last known valuation is $44.0M (Jan 2021).
- It has raised $63.2M across 5 recorded rounds; the latest was Early Stage VC ($13.0M) in Oct 2020.
- Notable investors include Johnson & Johnson Innovation - JLABS, Polaris Partners, Samsara BioCapital, CAM Capital, BioRock Ventures — 9 tracked in total.
- Primmune Therapeutics has filed 6 Form Ds with the SEC since 2017, most recently Nov 2020 ($13.0M sold to 12 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 5 rounds
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Primmune Therapeutics
Funding rounds
5 roundsAbout Primmune Therapeutics
Developer of an orally administered toll-like receptor agonist designed to stimulate innate immunity in cancer immunotherapy. The company's agonist produces cytokines and chemokines that up-regulate general cellular response and facilitate natural killer cell activation, enabling medical practitioners to address all metastatic diseases and stimulate B-cell proliferation and activation.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2017
- Employees
- 10
- Website
- primmunerx.com/
- Ownership
- Privately Held (backing)
Primmune Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Primmune Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Primmune Therapeutics in its N-PORT filings yet. We sweep new filings monthly.